Pharmaceutical Company Gilead Sciences Canada Joins the CATALIS Network
CATALIS is pleased to welcome the pharmaceutical company Gilead Sciences Canada Inc. to its Network of partners. Gilead joins numerous industry partners that are actively involved in the Network: Abbvie, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vertex.
These partners support CATALIS in its mission, which is to optimize Quebec’s clinical research environment and accelerate the development of innovative care for the benefit of the province’s patients.
“Gilead Sciences Canada is delighted to join the CATALIS Network to facilitate conducting its clinical trials in Quebec. In collaboration with stakeholders in Quebec’s ecosystem, Gilead will be able to help accelerate the development of new and innovative therapies and help provide earlier access to them for patients.” – Christophe Griolet, Vice President & General Manager, Gilead Sciences Canada
